Analysis of MET gene variation and clinicopathological characteristics of non-small cell lung cancer
10.13315/j.cnki.cjcep.2025.06.003
- VernacularTitle:非小细胞肺癌MET基因变异及临床病理特征分析
- Author:
Qiong ZHANG
1
;
Yang SHEN
;
Zhenhong JIANG
;
Jianping HU
;
Xinyu LONG
;
Zhiqing CHEN
;
Yuting RAO
;
Yan ZHENG
;
Yeqing ZOU
Author Information
1. 南昌大学第二附属医院分子医学江西省重点实验室,南昌 330006;南昌大学第二附属医院医学遗传科,南昌 330006;南昌大学公共卫生学院,南昌 330006
- Publication Type:Journal Article
- Keywords:
pulmonary neoplasms;
non-small cell lung cancer;
MET gene;
next-generation sequencing
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(6):713-718
- CountryChina
- Language:Chinese
-
Abstract:
Purpose The study aimed to analyze the relationship between MET gene variants and clinicopathologi-cal features in patients with non-small cell lung cancer(NSCLC).Methods Next-generation sequencing technology was used to detect MET gene variants in NSCLC specimens.The association between MET gene variant status and clini-copathological features was then analyzed.Results Among 1 633 cases of NSCLC,the overall MET mutation rate was 4.53％(74/1 633).Variants were mainly observed in male patients,never-smokers,those older than 60 years,ade-nocarcinoma histology,and patients with TNM stage Ⅲ+Ⅳ disease(P＜0.05).MET gene variant status showed no significant assocication with patient age,sex,smoking history,or pathological subtype(P＞0.05),but was statistical-ly correlated with clinical stage and presence of distant metastasis(P＜0.05).The two major variant types were MET exon 14 skipping and MET amplification,which together accounted for 71.62％of all variants.In addition,MET am-plification was positively correlated with EGFR(P=0.003,rs=0.340)and TP53 mutations(P=0.002,rs=0.362),but showed no correlation with KRAS or ALK gene mutations.In contrast,MET exon 14 skipping was nega-tively correlated with EGFR gene mutations(P＜0.001,rs=-0.409),and showed no significant correlation with KRAS,ALK,or TP53 mutations.Conclusion Different types of MET gene variants(amplification,exon 14 skip-ping,fusion,and others)are significantly associated with clinical advanced clinical stage and distant metastasis in NSCLC,but are independent of patient age,sex,smoking history,and pathological subtype.MET amplification fre-quently co-occur with EGFR and TP53 co-mutations.
